Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Xeris Biopharma Holdings (XERS) FCF Margin (2020 - 2025)

Historic FCF Margin for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to 24.78%.

  • Xeris Biopharma Holdings' FCF Margin rose 400800.0% to 24.78% in Q3 2025 from the same period last year, while for Sep 2025 it was 3.97%, marking a year-over-year increase of 207700.0%. This contributed to the annual value of 18.21% for FY2024, which is 104800.0% up from last year.
  • As of Q3 2025, Xeris Biopharma Holdings' FCF Margin stood at 24.78%, which was up 400800.0% from 0.25% recorded in Q2 2025.
  • Over the past 5 years, Xeris Biopharma Holdings' FCF Margin peaked at 24.78% during Q3 2025, and registered a low of 292.32% during Q1 2021.
  • In the last 5 years, Xeris Biopharma Holdings' FCF Margin had a median value of 48.63% in 2022 and averaged 77.36%.
  • In the last 5 years, Xeris Biopharma Holdings' FCF Margin surged by 1447100bps in 2022 and then crashed by -135400bps in 2024.
  • Xeris Biopharma Holdings' FCF Margin (Quarter) stood at 135.69% in 2021, then skyrocketed by 64bps to 48.63% in 2022, then surged by 135bps to 16.83% in 2023, then tumbled by -80bps to 3.29% in 2024, then surged by 654bps to 24.78% in 2025.
  • Its last three reported values are 24.78% in Q3 2025, 0.25% for Q2 2025, and 16.69% during Q1 2025.